Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma

Table 5 Comparison of liver and kidney function indicators (mean ± SD)

Group	Before treatment				After treatment
	Control group (n = 50)	Observation group (n = 50)	t value	P value	Control group (n = 50)	Observation group (n = 50)	t value	P value
TBIL (μmol/L)	22.07 ± 5.94	23.19 ± 6.05	0.933	0.353	18.74 ± 7.29	15.26 ± 6.02a	2.604	0.01
ALB (μmol/L)	36.56 ± 6.07	35.79 ± 6.18	0.628	0.532	35.29 ± 6.07	33.94 ± 6.67	1.059	0.292
ALT (μmol/L)	42.93 ± 7.85	41.05 ± 7.94	1.19	0.237	35.17 ± 8.93	26.88 ± 7.49a	5.03	< 0.001
AST (μmol/L)	59.41 ± 8.53	56.98 ± 9.04	1.383	0.17	50.87 ± 6.94	51.46 ± 6.53	0.438	0.662
Cr (μmol/L)	57.94 ± 11.97	57.04 ± 1 1.86	0.377	0.707	52.37 ± 6.94	51.86 ± 7.08	0.364	0.716
UA (μmol/L)	285. 67 ± 25.86	281.96 ± 32.45	0.632	0.529	273.49 ± 35.37	268.51 ± 30.46	0.755	0.452

^aP < 0.05 compared with the control group.

TBIL: Total bilirubin; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.